Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.
Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, Spencer A. Mithraprabhu S, et al. Among authors: ramachandran m. Br J Haematol. 2021 Apr;193(1):160-170. doi: 10.1111/bjh.17080. Epub 2020 Sep 18. Br J Haematol. 2021. PMID: 32945549 Free PMC article. Clinical Trial.
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.
Mithraprabhu S, Morley R, Khong T, Kalff A, Bergin K, Hocking J, Savvidou I, Bowen KM, Ramachandran M, Choi K, Wong BKL, Reynolds J, Spencer A. Mithraprabhu S, et al. Among authors: ramachandran m. Leukemia. 2019 Aug;33(8):2022-2033. doi: 10.1038/s41375-019-0469-x. Epub 2019 Apr 16. Leukemia. 2019. PMID: 30992504
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A, Khong T, Mithraprabhu S, Savvidou I, Hocking J, Bergin K, Ramachandran M, Chen M, Dammacco F, Ria R, Silvestris F, Vacca A, Reynolds J, Spencer A. Reale A, et al. Among authors: ramachandran m. Leuk Lymphoma. 2021 Feb;62(2):337-347. doi: 10.1080/10428194.2020.1832659. Epub 2020 Oct 31. Leuk Lymphoma. 2021. PMID: 33131357
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A. Kalff A, et al. Among authors: ramachandran m. Leuk Lymphoma. 2021 Dec;62(12):2981-2991. doi: 10.1080/10428194.2021.1948030. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263697 Clinical Trial.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Kalff A, et al. Among authors: ramachandran m. Haematologica. 2022 Jan 1;107(1):321-325. doi: 10.3324/haematol.2021.278655. Haematologica. 2022. PMID: 34587718 Free PMC article. No abstract available.
382 results